Nurix Total Assets from 2010 to 2025

NRIX Stock

USD 20.02 0.37 1.88%

Nurix Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-11-30

Previous Quarter

513.6 M

Current Value

669.3 M

Quarterly Volatility

142.8 M

Covid

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.

Check out the analysis of Nurix Therapeutics Correlation against competitors.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Nurix Therapeutics over the last few years. Total assets refers to the total amount of Nurix Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nurix Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Nurix Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 669.34 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Nurix Total Assets Regression Statistics

	Arithmetic Mean	268,750,883
	Geometric Mean	132,718,433
	Coefficient Of Variation	107.03
	Mean Deviation	251,441,743
	Median	45,397,000
	Standard Deviation	287,645,164
	Sample Variance	82739.7T
	Range	764.2M
	R-Value	0.88
	Mean Square Error	19358.8T
	R-Squared	0.78
	Slope	53,414,919
	Total Sum of Squares	1241096.1T

Nurix Total Assets History

	2025	808.2 M
	2024	769.7 M
	2023	669.3 M
	2022	355.6 M
	2021	416.8 M
	2020	476.8 M
	2019	396.3 M

Other Fundumenentals of Nurix Therapeutics

Intangibles To Total Assets

Nurix Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.86	0.7	-0.77	-0.91	0.97	0.98	0.95	0.88	1.0	0.99	0.99	0.99	0.76	0.99	0.8	-0.88	-0.67
Total Stockholder Equity	1.0		0.86	0.7	-0.78	-0.9	0.97	0.98	0.94	0.86	1.0	0.99	0.99	0.99	0.74	0.99	0.79	-0.86	-0.67
Net Tangible Assets	0.86	0.86		0.81	-0.74	-0.79	0.76	0.78	0.93	0.89	0.86	0.8	0.86	0.8	0.89	0.86	0.9	-0.82	-0.28
Current Deferred Revenue	0.7	0.7	0.81		-0.38	-0.72	0.67	0.67	0.79	0.74	0.7	0.67	0.72	0.64	0.74	0.72	0.79	-0.77	-0.3
Net Debt	-0.77	-0.78	-0.74	-0.38		0.52	-0.63	-0.67	-0.66	-0.55	-0.78	-0.73	-0.72	-0.75	-0.5	-0.72	-0.49	0.43	0.38
Retained Earnings	-0.91	-0.9	-0.79	-0.72	0.52		-0.94	-0.95	-0.93	-0.9	-0.9	-0.93	-0.94	-0.92	-0.81	-0.94	-0.77	0.97	0.57
Accounts Payable	0.97	0.97	0.76	0.67	-0.63	-0.94		0.99	0.91	0.88	0.97	0.99	0.98	0.98	0.7	0.98	0.76	-0.89	-0.74
Short Term Investments	0.98	0.98	0.78	0.67	-0.67	-0.95	0.99		0.92	0.86	0.98	1.0	0.99	0.99	0.71	0.99	0.73	-0.89	-0.73
Capital Surpluse	0.95	0.94	0.93	0.79	-0.66	-0.93	0.91	0.92		0.92	0.94	0.93	0.97	0.92	0.91	0.97	0.87	-0.95	-0.55
Total Liab	0.88	0.86	0.89	0.74	-0.55	-0.9	0.88	0.86	0.92		0.86	0.86	0.9	0.85	0.88	0.9	0.88	-0.89	-0.44
Net Invested Capital	1.0	1.0	0.86	0.7	-0.78	-0.9	0.97	0.98	0.94	0.86		0.99	0.99	0.99	0.74	0.99	0.79	-0.86	-0.67
Total Current Assets	0.99	0.99	0.8	0.67	-0.73	-0.93	0.99	1.0	0.93	0.86	0.99		0.99	1.0	0.71	0.99	0.73	-0.87	-0.72
Capital Stock	0.99	0.99	0.86	0.72	-0.72	-0.94	0.98	0.99	0.97	0.9	0.99	0.99		0.99	0.79	1.0	0.79	-0.91	-0.68
Net Working Capital	0.99	0.99	0.8	0.64	-0.75	-0.92	0.98	0.99	0.92	0.85	0.99	1.0	0.99		0.7	0.99	0.72	-0.86	-0.72
Short Term Debt	0.76	0.74	0.89	0.74	-0.5	-0.81	0.7	0.71	0.91	0.88	0.74	0.71	0.79	0.7		0.79	0.8	-0.88	-0.31
Common Stock	0.99	0.99	0.86	0.72	-0.72	-0.94	0.98	0.99	0.97	0.9	0.99	0.99	1.0	0.99	0.79		0.79	-0.91	-0.68
Property Plant Equipment	0.8	0.79	0.9	0.79	-0.49	-0.77	0.76	0.73	0.87	0.88	0.79	0.73	0.79	0.72	0.8	0.79		-0.84	-0.27
Net Receivables	-0.88	-0.86	-0.82	-0.77	0.43	0.97	-0.89	-0.89	-0.95	-0.89	-0.86	-0.87	-0.91	-0.86	-0.88	-0.91	-0.84		0.52
Deferred Long Term Liab	-0.67	-0.67	-0.28	-0.3	0.38	0.57	-0.74	-0.73	-0.55	-0.44	-0.67	-0.72	-0.68	-0.72	-0.31	-0.68	-0.27	0.52

Click cells to compare fundamentals

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	769.7 M	808.2 M
Intangibles To Total Assets	(0.01)	(0.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC